Replies to post #631463 on NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

Sure appears from this relatively small trial that dcvax needs the adjuvant polyICLC and results in great improvement.

It certainly seems that there is a benefit to adding the Poly ICLC... however, the single methylated GBM placebo patient (on DCVax only) lived past 5 years (actually the longest of all the patients at 61.2 months). The remaining placebo patients were all unmethylated, and so on DCVax-L alone, they didn't fare as well. But when you put the Poly ICLC in the mix, the four unmethylated alone (not including the methylated who lied 52.5 months) had a mOS of 28.6, and all of them (remember, all unmethylated!) lived over 24.5 months (which was the lowest mOS). So it appears that they are improving on the mOS of the unmethylated with the Poly ICLC.